ZAI LAB LIMITED Finite-Lived Intangible Asset, Expected Amortization, Year One
ZAI LAB LIMITED (ZLAB) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $7.29 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $7.29M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $5.83M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $3.10M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $600.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $7.29M 10-K · filed 2026-02-26 |
| 2024-12-31 | $5.83M 10-K · filed 2025-02-27 |
| 2023-12-31 | $3.10M 10-K · filed 2024-02-27 |
| 2022-12-31 | $600.00K 10-K · filed 2023-03-01 |
| 2021-12-31 | $570.00K 10-K · filed 2022-03-01 |
| 2019-12-31 | $255.00K 20-F · filed 2020-04-29 |
| 2018-12-31 | $206.88K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |